OncoMatch/Clinical Trials/NCT06169072
Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients
Is NCT06169072 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Superparamagnetic Iron Oxide and Technetium99 for breast cancer.
Treatment: Superparamagnetic Iron Oxide · Technetium99 — The overall aim is to demonstrate that the use of superparamagnetic iron oxide nanoparticles (SPIO) as a tracer in an ultra-low dose (0.1 ml) is non-inferior for sentinel lymph node (SLN) detection in patients with breast cancer compared to the dual technique using Tc99m +/- blue dye, and to evaluate MRI breast artefacts and skin staining over time.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06169072 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages